TAP Partner News During SITC: Nov 2021
TAP Partner News During SITC: Nov 2021
Immune-Onc Therapeutics to Present Data Supporting Therapeutic Potential of LAIR1 Antagonist Antibodies at SITC Annual Meeting
PALO ALTO, CA, November 9, 2021 - Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced that the Company will present a scientific poster at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021) being held November 10-14, 2021, in Washington, D.C., USA.
Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming SITC Annual Meeting
Krakow, Poland – November 9, 2021 – Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology announced today that it will present two research posters on its HPK1 and STING programs at the upcoming Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021) taking place on November 10 – 14, 2021, in Washington, DC.
Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at 2021 SITC Annual Meeting
WATERTOWN, Mass., Nov. 04, 2021 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the Company will present new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, taking place from November 10 - 14, 2021 in Washington, D.C.
NexImmune to Present at 2021 SITC Annual Meeting
GAITHERSBURG, Md., Nov. 03, 2021 - NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that two abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting in Washington, D.C., being held November 10-14, 2021.
CARISMA Announces Multiple Abstracts Accepted for Presentation at 2021 SITC Annual Meeting
PHILADELPHIA, November 1, 2021 — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the acceptance of a late breaker abstract for oral presentation of its clinical study data and three pre-clinical study abstracts to be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting (November 10 – 14, 2021) in Washington, D.C.
Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at 2021 SITC Annual Meeting
Heidelberg, Germany, October 01, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three abstracts with preclinical data of its innate cell engagers have been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held on November 10-14, 2021.